Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC),...
Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more


Broadfin Capital Picked Up Alphatec Holdings Inc. (N...
Uluru Inc. (OTCMKTS:ULUR) is Attracting Smart Money
Easton Pharmaceuticals Inc (OTCMKTS:EAPH) to Acquire...

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Oncomed Pharmaceuticals Inc (NASDAQ:OMED) reported that Biotechnology Value Fund L P has picked up 1,372,923 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned byBiotechnology Value Fund L P to a total of 1,372,923 representing less than 3.6% stake in the company.

For those not familiar with the company, OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

A glance at Oncomed Pharmaceuticals Inc (NASDAQ:OMED)’s key stats reveals a current market capitalization of 160.50 Million based on 37.62 Million shares outstanding and a price at last close of $4.00 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-09-30, Lasersohn picked up 9,120 at a purchase price of $16.26. This brings their total holding to 46,560 as of the date of the filing.

On the sell side, the most recent transaction saw Lewicki unload 5,711 shares at a sale price of $9.06. This brings their total holding to 22,937.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Oncomed Pharmaceuticals Inc (NASDAQ:OMED) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.




Stay in the lopp :

Global Consortium Inc. (OTCMKTS:GCGX) Negotia...

The shares of Global Consortium Inc. (OTCMKTS:GCGX) continues to move higher and gains another 6% in Wednesday's session. The stock has gained

Baozun BZUN Stock Price is tanking, but I fou...

Baozun BZUN stock price is down 12% in the last 5 days & volume is up 290%, but is it over for

Here's Who Just Picked Up Silver Bay Realty T...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Silver Bay Realty Trust Corp. (NYSE:SBY) reported that Kessler Irvin

related post

Skip to content